Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
AEMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.08 - $8.44
Previous CloseN/A
Volume1.62M
Average Volume (3M)364.99K
Market Cap
$2.94M
Enterprise Value-$586.88K
Total Cash (Recent Filing)$3.77B
Total Debt (Recent Filing)$573.85M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 18, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding2,598,711
10 Day Avg. Volume745,522
30 Day Avg. Volume364,989
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.20
Enterprise Value/Revenue-3.41
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$1.50Price Target Upside-5.66% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe first cohort of three patients in the Australian Hemopurifier cancer trial were treated without device-related serious adverse events, and the Data Safety Monitoring Board recommended advancing to the second treatment cohort.
Regulatory ApprovalAEMD received formal approval from India's Central Drugs Standard Control Organization to initiate a similar oncology trial at Medanta Medicity Hospital.
Bears Say
Commercialization UncertaintyCapital constraints and clinical uncertainty continue to weigh on visibility, maintaining a Hold rating due to the uncertain commercialization timeline of the Hemopurifier.
Financial PerformanceAethlon reported results for 1Q FY 2026 with no revenues and a net loss of $0.85 per diluted share.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $1.08 and its highest was $8.44 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $2.94M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2025 which is in 87 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.861 by $0.011.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -0.51.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 2,598,711 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.861. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
Aethlon Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (-5.66% Downside)
$1.50 (-5.66% Downside)
Blogger Sentiment
Bullish
AEMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.3%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.49%
12-Months-Change
Fundamentals
Return on Equity
-207.29%
Trailing 12-Months
Asset Growth
-53.52%
Trailing 12-Months
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. (AEMD) is a biotechnology company focused on developing innovative therapies for life-threatening diseases. The company primarily operates in the healthcare sector, offering medical devices and therapeutic solutions aimed at addressing unmet medical needs, particularly in the areas of oncology and infectious diseases. Aethlon's flagship product, the Hemopurifier, is a first-in-class device designed to selectively filter and remove harmful viruses and exosomes from the bloodstream, which can contribute to disease progression and immune suppression.
AEMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call had a positive tone overall, with significant progress reported in the Australian oncology trial and promising preclinical data in long COVID. Financial management showed effective cost reduction and strategic refocusing, although some setbacks were noted with the discontinuation of the Indian trial and a patient death in the trial.View all AEMD earnings summariesAEMD Stock 12 Month Forecast
Average Price Target
$1.50
▼(-5.66% Downside)
Technical Analysis
Trinity Biotech
―
Purple Biotech
―
Aytu BioScience
―
BioNano Genomics
―
Mainz Biomed B.V.
―
Ownership Overview
15.59% Insiders
0.82% Mutual Funds
14.76% Other Institutional Investors
68.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---